Humana Inc. (HUM) Insider Elizabeth D. Bierbower Sells 9,786 Shares

Humana Inc. (NYSE:HUM) insider Elizabeth D. Bierbower sold 9,786 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $259.00, for a total value of $2,534,574.00. Following the sale, the insider now directly owns 18,042 shares in the company, valued at approximately $4,672,878. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Shares of Humana Inc. (HUM) opened at 249.28 on Friday. Humana Inc. has a 12 month low of $163.50 and a 12 month high of $259.76. The stock has a 50 day moving average price of $250.25 and a 200 day moving average price of $231.50. The stock has a market cap of $36.03 billion, a P/E ratio of 20.51 and a beta of 0.87.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, beating the Zacks’ consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The business had revenue of $13.53 billion for the quarter, compared to analyst estimates of $13.61 billion. During the same quarter in the prior year, the business earned $2.30 EPS. Equities analysts anticipate that Humana Inc. will post $11.55 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Tuesday, August 29th will be given a dividend of $0.40 per share. The ex-dividend date is Thursday, September 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.64%. Humana’s payout ratio is presently 13.06%.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/09/16/insider-selling-humana-inc-hum-insider-sells-2534574-00-in-stock.html.

Several large investors have recently made changes to their positions in the business. BlackRock Inc. grew its position in shares of Humana by 2,281.7% during the 1st quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock worth $2,553,487,000 after purchasing an additional 11,867,056 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Humana by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 9,892,635 shares of the insurance provider’s stock worth $2,380,366,000 after purchasing an additional 157,868 shares in the last quarter. FMR LLC grew its position in shares of Humana by 29.3% during the 2nd quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock worth $1,571,264,000 after purchasing an additional 1,479,210 shares in the last quarter. State Street Corp grew its position in shares of Humana by 1.4% during the 1st quarter. State Street Corp now owns 6,274,811 shares of the insurance provider’s stock worth $1,293,487,000 after purchasing an additional 84,716 shares in the last quarter. Finally, Capital Research Global Investors grew its position in shares of Humana by 9.7% during the 2nd quarter. Capital Research Global Investors now owns 3,907,333 shares of the insurance provider’s stock worth $940,182,000 after purchasing an additional 346,069 shares in the last quarter. Hedge funds and other institutional investors own 95.14% of the company’s stock.

Several research analysts have weighed in on HUM shares. BidaskClub raised Humana from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. ValuEngine raised Humana from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $255.00 price objective for the company in a report on Tuesday, June 13th. Argus raised Humana from a “hold” rating to a “buy” rating and set a $260.00 price objective for the company in a report on Friday, June 9th. Finally, Morgan Stanley boosted their price target on Humana from $269.00 to $276.00 and gave the stock an “overweight” rating in a report on Thursday, August 17th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $244.35.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Insider Buying and Selling by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Humana Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply